What Is The Difference Between Monoclonal And Polyclonal Antibody?
Antibodies are proteins secreted by the immune system's B cells to recognize, bind, and neutralize antigens that are unique to organisms such as viruses and bacteria. Antibodies, because of their role in the detection and identification of antigens, can serve as a lifeline for scientific, clinical research, and diagnosis4.
These antigens are usually proteins, but can also be nucleotides, small molecules, or macromolecules. The ability of an antibody to bind to an antigen effectively depends on the sequence of antigen-binding surfaces, known as the epitope, and how well the epitope matches the antibody-binding surface sequence.
Antibodies are structured as Y-shaped molecules, with the tail end being responsible for effector function and allowing the antibody to interact with other cells of the immune system.
The technique for producing monoclonal/polyclonal antibodies relies on the ability to stimulate the continuous production of antibodies in host cells, which are then collected and purified for research and clinical use. You can get details on rabbit monoclonal antibody service via www.bosterbio.com/rabbit-monoclonal-antibodies.
What is the difference between Monoclonal and Polyclonal Antibody?
When immunogens (antigens) are injected into animals, cells of the primary immune response secrete various antibodies that recognize and bind to multiple antigen epitopes. Because secreted antibodies are produced by many plasma cells, they are called polyclonal antibodies.
On the other hand, monoclonal antibodies are said to be produced by the same B cells which are clones of a single stem cell. This means that monoclonal antibodies can only recognize and bind to the same antigen epitope, reducing the risk of cross-reactivity.
Polyclonal antibodies are usually made in vivo and monoclonal antibodies are made ex vivo, making it easier to standardize. Although monoclonal and polyclonal antibodies have advantages and disadvantages for use as research tools, the heterogeneity of polyclonal antibodies limits their development, validation, and use. Therefore, monoclonal antibodies are generally preferred over polyclonal antibodies.